Atlanta, GA – Scibility Media – 10/31/2014.
This article discusses two companies: Insulet Corporation(NASDAQ:PODD) and IDEX Corporation(NYSE:IEX)
Insulet Corporation(NASDAQ:PODD) is a medical instruments and supplies company that sells insulin infusion systems for individuals with insulin-dependent diabetes. The company recently entered into an Investigator-Initiated Research Agreement with Capricor Therapeutics, through which Insulet will assist in certain product development, project management, and design control activities.
The Massachusetts-based company will be reporting its third quarter financial results after the markets close on Nov. 5th, 2014. Additionally, Insulet Corporation will also be hosting a conference call on that date to discuss the figures. Representatives from the company will also discuss its operations, prospects for growth, and strategies. Insult has a market capitalization of over $2 billion.
IDEX Corporation(NYSE:IEX) reported its third quarter financial results on Oct. 20th, 2014. The figures included a 9% increase in sales, an earnings per share figure of $0.88, and a free cash flow of $92 million. Overall, the company had a 12% increase in income, a 90 basis points gross margin boost, and a 100 basis points operating margin increase year-over-year.
The Illinois-based diversified machinery company provides pumps, flow meters, and engineered products. IDEX operates through its Fluid & Metering Technologies, Health & Science Technologies, and Fire & Safety / Diversified Products segment, the latter of which provides firefighting pumps and controls and other rescue tools.
EquiPress.com is a non-advertisement based network (currently in limited release) designed for investors to discover and communicate with publicly traded companies in real-time.
Sign-up for free now to experience the full benefits of EquiPress pre-launch.
Discover and communicate with companies you would otherwise never have seen based on your interests, company news, personalized news feeds, and one-on-one communications with no middle-men nor advertisements. Read our no advertisements pledge.
Can’t find your company on EquiPress? Send us an email to email@example.com and we will contact them for you.
Interested in a one month free trial? Get access to our private investor network, real-time news distribution, automatic disclaimers, corporate analytics, verified public profile, and industry-wide marketing of your corporate news.
Disclosure: EquiPress is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. EquiPress does not hold any equity or financial interest in any publicly traded company. EquiPress provides a uniform subscription based service to all publicly traded companies on a monthly basis at a rate of $495 to provide investor awareness. EquiPress receives only cash compensation from clients. Despite the relationship, EquiPress maintains a neutral stance (nonbiased) on any investment related opinions and exists solely for the purpose of allowing investors to communicate with the publicly traded companies in an effort to establish for themselves investment considerations. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor. Please visit www.equipress.com for complete risks and disclosures.